Taysha Gene Therapies Quote - TSHA

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

2.78

Bid

2.74

Offer

2.79

Volume

3,177,460

2.74 Day's Range 3.125

0.00 52 Week Range 0.00

Market Cap

517.88M

Previous Close

2.97

Open

2.93

Last Trade

200

2.78

(formt)

Last Trade Time

07:43:20

Financial Volume

US$ 9,038,722

VWAP

2.8446

Average Volume (3m)

Shares Outstanding

186,960,193

Dividend Yield

PE Ratio

-4.64

Earnings Per Share (EPS)

-0.6

Revenue

15.45M

Net Profit

-111.57M

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and com... Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.tayshagtx.com

Headquarters

Dover, Delaware, USA

Founded

1970

Taysha Gene Therapies Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker TSHA. The last closing price for Taysha Gene Therapies was US$2.97. Over the last year, Taysha Gene Therapies shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Taysha Gene Therapies currently has 186,960,193 shares in issue. The market capitalisation of Taysha Gene Therapies is US$517.88 million. Taysha Gene Therapies has a price to earnings ratio (PE ratio) of -4.64.

Form 8-K - Current report

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging...

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
1ADAdAlta Limited	AUD 0.026 (0.00%)	0
14DO1414 Degrees Limited	AUD 0.008 (0.00%)	0
14DN1414 Degrees Limited	AUD 0.00 (0.00%)	0
14D1414 Degrees Limited	AUD 0.066 (0.00%)	0
13S13 Seeds Limited	0.00 (0.00%)	0
1ADAdAlta Limited	AUD 0.026 (0.00%)	0
14DO1414 Degrees Limited	AUD 0.008 (0.00%)	0
14DN1414 Degrees Limited	AUD 0.00 (0.00%)	0
14D1414 Degrees Limited	AUD 0.066 (0.00%)	0
13S13 Seeds Limited	0.00 (0.00%)	0
TAHTabcorp Holdings Limited	AUD 1.31 (0.00%)	13.58M
SGRStar Entertainment Group Limited	AUD 2.94 (0.00%)	6.49M
NABNational Australia Bank Limited	AUD 37.01 (0.00%)	5.04M
MGRMirvac Group	AUD 2.41 (0.00%)	4.34M
AWCAlumina Limited	AUD 3.01 (0.00%)	3.73M